Evidence map›Paper›PMID 32546227›Full record

ArticleThe journal of headache and pain2020

European headache federation consensus on the definition of resistant and refractory migraine : Developed with the endorsement of the European Migraine & Headache Alliance (EMHA).

Simona Sacco, Mark Braschinsky, Anne Ducros, Christian Lampl, Patrick Little, Antoinette Maassen van den Brink, Patricia Pozo-Rosich, Uwe Reuter, Elena Ruiz de la Torre, Margarita Sanchez Del Rio and 3 more

2 registry-linked trialsOpen access · goldAbstract readConsensus Statement
In one paragraph

Article in The journal of headache and pain, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 101 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 3 pooled it
23.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05046119 unknown statusnot on this mapstarted 2021, after this paper: background citation

Factors Associated With Migraine Refractoriness to Preventive Treatments: Psychological Aspects and Relationship With Components of the Endocannabinoid System

TypeobservationalSponsorIRCCS National Neurological Institute "C. Mondino" FoundationRan2021 to 2024Enrolled80ConditionsMigraine
NCT05442008 completednot on this map

Study of Early MIDAS Reduction at 3 Months as Predictor of Long-term Erenumab Treatment in Chronic Migraine: a Real-life, Open-label, Trial

TypeobservationalSponsorIRCCS National Neurological Institute "C. Mondino" FoundationRan2018 to 2021Enrolled53ConditionsMigraineArmsErenumab 70/140 mg s.c.
3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 3 syntheses or guidelines pooled it, 253 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Effectiveness of atogepant in migraine with and without medication overuse: Pooled real-world analysis of two independent clinical cohorts.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Observational
  12. Article
  13. Observational
  14. Observational
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Observational

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 10 countries.

Simona SaccoNeuroscience section - Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy. simona.sacco@univaq.it.ORCID http://orcid.org/0000-0003-0651-1939
Mark BraschinskyHeadache Clinic, Department of Neurology, Tartu University Clinics, Tartu, Estonia.
Anne DucrosHeadache Unit, Neurology Department, Montpellier University Hospital and Montpellier University, Montpellier, France.
Christian LamplDepartment of Neurology, Headache Medical Centre Linz, Hospital Barmherzige Brüder, Centre of Integrative Medicine (ZiAM) Ordensklinikum Linz, Linz, Austria.
Patrick LittleEuropean Migraine & Headache Alliance (EMHA), Hendrik Ido Ambacht, The Netherlands.
Antoinette Maassen van den BrinkDivision of Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Patricia Pozo-RosichHeadache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Uwe ReuterCharité Universitätsmedizin Berlin, Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Elena Ruiz de la TorreEuropean Migraine & Headache Alliance (EMHA), Hendrik Ido Ambacht, The Netherlands.
Margarita Sanchez Del RioNeurology department, Clinica Universidad de Navarra, Madrid, Spain.
Alexandra J SinclairMetabolic Neurology, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Zaza KatsaravaEvangelical Hospital Unna, Unna, Germany.
Paolo MartellettiDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Birmingham Dental Hospital · GBCharité - Universitätsmedizin Berlin · DEClinica Universidad de Navarra · ESCTO Andrea Alesini · ITErasmus MC · NLHebron University · PSKrankenhaus der Elisabethinen · ATSechenov University · RUTartu University Hospital · EEUniversité de Montpellier · FRUniversity of L'Aquila · IT

Funding

Department of Health NIHR-CS-011-028Medical Research Council MR/K015184/1
6 · The paper itself

Abstract

introductionDespite advances in the management of headache disorders, some patients with migraine do not experience adequate pain relief with acute and preventive treatments. It is the aim of the present document to provide a definition of those migraines which are difficult-to-treat, to create awareness of existence of this group of patients, to help Healthcare Authorities in understanding the implications, and to create a basis to develop a better pathophysiological understanding and to support further therapeutic advances. MAIN BODY: Definitions were established with a consensus process using the Delphi method. Patients with migraine with or without aura or with chronic migraine can be defined as having resistant migraine and refractory migraine according to previous preventative failures. Resistant migraine is defined by having failed at least 3 classes of migraine preventatives and suffer from at least 8 debilitating headache days per month for at least 3 consecutive months without improvement; definition can be based on review of medical charts. Refractory migraine is defined by having failed all of the available preventatives and suffer from at least 8 debilitating headache days per month for at least 6 consecutive months. Drug failure may include lack of efficacy or lack of tolerability. Debilitating headache is defined as headache causing serious impairment to conduct activities of daily living despite the use of pain-relief drugs with established efficacy at the recommended dose and taken early during the attack; failure of at least two different triptans is required.

conclusionsWe hope, that the updated EHF definition will be able to solve the conflicts that have limited the use of definitions which have been put forward in the past. Only with a widely accepted definition, progresses in difficult-to-treat migraine can be achieved. This new definition has also the aim to increase the understanding of the impact of the migraine as a disease with all of its social, legal and healthcare implications. It is the hope of the EHF Expert Consensus Group that the proposed criteria will stimulate further clinical, scientific and social attention to patients who suffer from migraine which is difficult-to-treat.

Indexed as

Activities of Daily LivingAnalgesicsEuropeFemaleHumansIntractable PainMaleMiddle AgedMigraine DisordersTryptaminesAnalgesicsTryptaminesChronic migraineIntractable migraineMigraineRefractory migraineResistant migraine

Identifiers

PMID32546227
PMCPMC7296705
OpenAlexW3035231691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.